Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain PLSE message board posts where the ticker symbol PLSE has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest PLSE SEC Filings

Filings Format Description Filing Date File/Film Number
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001625101-18-000045 (34 Act)  Size: 4 MB
2018-07-31 001-37744
18981377
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001625101-18-000043 (34 Act)  Size: 212 KB
2018-07-31 001-37744
18981204
8-K  Documents Current report, item 3.01
Acc-no: 0001625101-18-000041 (34 Act)  Size: 35 KB
2018-07-31 001-37744
18981117
8-K12B  Documents Notification that a class of securities of successor issuer is deemed to be registered pursuant to section 12(b), items 1.01, 3.03, 5.03, 8.01, and 9.01
Acc-no: 0001625101-18-000036 (34 Act)  Size: 963 KB
2018-06-18 001-37744
18905215
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-035292 Size: 5 KB
2018-06-04
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-033158 Size: 5 KB
2018-05-24
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-033155 Size: 5 KB
2018-05-24
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-033152 Size: 5 KB
2018-05-24
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-033150 Size: 5 KB
2018-05-24
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-033146 Size: 5 KB
2018-05-24
More PLSE SEC Filings


Related news from
Mon, 15 Oct 2018
20:24:00 +0000
Pulse Biosciences Grants Equity Incentive Awards to New Employees
Pulse Biosciences, Inc. (PLSE), a novel medical therapy company bringing to market its proprietary Nano-Pulse Stimulation™ platform, announced today that the Compensation Committee of the company’s Board of Directors granted non-qualified stock options covering an aggregate of 20,750 shares of Pulse Biosciences common stock to four new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on October 15, 2018. The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individual's entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).
Thu, 11 Oct 2018
12:00:00 +0000
Pulse Biosciences Announces Continued Expansion of Its Clinical Study Programs in Dermatology
Fourth Dermatology Study Will Evaluate Nano-Pulse Stimulation™ in Treating Cutaneous Warts
Tue, 09 Oct 2018
15:26:16 +0000
What Kind Of Risk Should You Expect For Pulse Biosciences Inc (NASDAQ:PLSE)?
Anyone researching Pulse Biosciences Inc (NASDAQ:PLSE) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory.<div><a class="permalink" href="https://simplywall.st/news/yahoo-post/what-kind-of-risk-should-you-expect-for-pulse-biosciences-inc-nasdaqplse/">Read More...</a></div>
Mon, 01 Oct 2018
22:18:00 +0000
Pulse Biosciences to Present at the Cantor Global Healthcare Conference
Pulse Biosciences, Inc. , a novel medical therapy company bringing to market its proprietary Nano-Pulse Stimulation™ platform, announced today that Darrin Uecker, President and Chief Executive Officer, is scheduled to present at the Cantor Global Healthcare Conference in New York at 4:00 p.m.
Mon, 13 Aug 2018
20:01:00 +0000
Robbins Arroyo LLP Is Investigating the Officers and Directors of Pulse Biosciences, Inc. (PLSE) on Behalf of Shareholders
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Pulse Biosciences, Inc. breached their fiduciary duties to shareholders.
Tue, 31 Jul 2018
20:00:00 +0000
Pulse Biosciences Quarterly Investor Conference Call
Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT
Tue, 31 Jul 2018
18:30:00 +0000
Pulse Biosciences, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Pulse Biosciences, Inc. (NASDAQ: PLSE ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 31, 2018 at 4:30 PM Eastern Time. ...
Mon, 30 Jul 2018
20:55:00 +0000
Pulse Biosciences Treats Initial Patient in Its Human Study Evaluating the Effects of Nano-Pulse Stimulation in Basal Cell Carcinoma
Pulse Biosciences, Inc. (PLSE) today announced the treatment of the first patient in a clinical study to evaluate Nano-Pulse Stimulation (NPS) in a common skin cancer, Basal Cell Carcinoma (BCC). Patients in the study will be treated with NPS prior to resection of the BCC lesion, which is the standard of care for BCC lesions. Post resection tissue samples will be assessed for elimination of the BCC lesion in the NPS treatment zone and for biomarkers indicating an immune response to the NPS-treated BCC lesions.
Thu, 12 Jul 2018
18:30:00 +0000
Pulse Biosciences to Report Second Quarter 2018 Financial Results and Operational Highlights
Pulse Biosciences, Inc. , a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation platform, today announced that the Company will report second quarter 2018 operational highlights and financial results on Tuesday, July 31, 2018.
Tue, 10 Jul 2018
20:00:00 +0000
Pulse Biosciences Announces Treatment of First Patients in Study to Evaluate the Safety and Efficacy of Novel Nano-Pulse Stimulation for the Treatment of Sebaceous Hyperplasia Lesions
Pulse Biosciences, Inc. (PLSE) today announced treatment of the first patients in its multicenter study to evaluate the safety and efficacy of its Nano-Pulse Stimulation (NPS) technology for eliminating Sebaceous Hyperplasia (SH), an unsightly benign skin lesion that typically appears on facial skin and is considered a difficult-to-treat condition with current modalities. NPS is a non-thermal technology that utilizes ultra-short, nanosecond pulsed electrical fields to directly affect cell membranes and intracellular structures while sparing non-cellular tissues.
Wed, 20 Jun 2018
12:00:00 +0000
Kaskela Law LLC Announces Investigation of Pulse Biosciences, Inc. on Behalf of Stockholders
RADNOR, PA / ACCESSWIRE / June 20, 2018 / Kaskela Law LLC is investigating Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE) on behalf of the Company's stockholders. ...
Mon, 30 Apr 2018
20:01:00 +0000
Pulse Biosciences to Report First Quarter 2018 Financial Results and Operational Highlights
Pulse Biosciences, Inc. , a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation platform, today announced that the Company will report first quarter 2018 financial results and operational highlights on Tuesday, May 8, 2018.
Wed, 18 Apr 2018
20:00:00 +0000
Pulse Biosciences Grants Equity Incentive Awards to New Employee
Pulse Biosciences, Inc. , a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation platform, today announced that the Compensation Committee of the company’s Board of Directors granted non-qualified stock options covering an aggregate of 300,000 shares of Pulse Biosciences common stock to one new employee under the Pulse Biosciences 2017 ...
Fri, 13 Apr 2018
20:32:00 +0000
Why Alaska Air Group, Pulse Biosciences, and BJ's Restaurants Jumped Today
Learn which companies rose on better business conditions in their industry.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum is the gold standard, valuable because of the exceptional people who post here, and because the best of them are candid, detailed and informed. There is little tolerance for the b.s. found on public boards, and management and members are vigilant and aggressive about TOS violations. VF is the gold standard." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards